For UK private clinics
Either too cautious to compete or one complaint away from enforcement
UK aesthetic and private healthcare marketing sits inside overlapping ASA and CQC frameworks that most clinics misread in one direction or the other. The result is either invisible marketing or avoidable regulatory exposure.
Two minutes. Solva follows up with specific compliant marketing options.
- Advertisements being removed from circulation by the ASA
- Public complaints leading to formal investigations
- Negative media coverage regarding non-compliant marketing
- CQC inspections flagging marketing materials as misleading
- Diversion of staff time to address compliance issues
- Delays in marketing campaign launches
- Loss of revenue from withdrawn campaigns
- Potential fines and legal costs
- Damage to brand trust and credibility
- Negative public perception
In 2024, the ASA and CAP secured the amendment or withdrawal of 33,903 ads (ASA, 2024)
Frequently asked questions
Why does this problem persist?
Aesthetic and private healthcare marketing in the UK is tightly regulated. Most clinics either over-comply and produce bland, ineffective marketing, or under-comply and risk enforcement action. Neither is a good outcome.
What is the cost of leaving it unaddressed?
No verified UK data available for specific rework costs, but enforcement actions are costly (ASA, 2024)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.